Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.
暂无分享,去创建一个
J. Holst | P. Hellström | S. Efendić | S Efendic | J J Holst | T. Tolessa | P. M. Hellström | T Tolessa | M Gutniak | P M Hellström | M. Gutniak
[1] J. Holst,et al. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[2] J. Holst,et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. , 1997, American journal of physiology. Endocrinology and metabolism.
[3] J. Holst,et al. Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[4] T. Ljung,et al. Nitrergic inhibition of migrating myoelectric complex in the rat is mediated by vasoactive intestinal peptide , 1996, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[5] P. Hellström,et al. Characteristics of fasting and fed myoelectric activity in rat small intestine: evaluation by computer analysis. , 1996, Acta physiologica Scandinavica.
[6] J. Holst,et al. Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat Pancreas , 1996, Diabetes Care.
[7] J. Raufman. Bioactive peptides from lizard venoms , 1996, Regulatory Peptides.
[8] J. Holst,et al. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.
[9] M. Jimenez,et al. Is nitric oxide the final mediator regulating the migrating myoelectric complex cycle? , 1995, The American journal of physiology.
[10] B. Göke,et al. Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9–39) Amide , 1995, Diabetes.
[11] N. Wiklund,et al. Nitric oxide-like activity in guinea pig colon as determined by effector responses, bioassay and chemiluminescence analysis. , 1994, Acta physiologica Scandinavica.
[12] J. Holst,et al. Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.
[13] S. Sarna,et al. Nitric oxide regulates migrating motor complex cycling and its postprandial disruption. , 1993, The American journal of physiology.
[14] P. Hellström,et al. Myoelectric pattern and effects on small bowel transit induced by the tachykinins neurokinin A, neurokinin B, substance P and neuropeptide K in the rat , 1993 .
[15] P. Hellström,et al. Computer program MMC' to summarize characteristics of activity fronts of migrating myoelectric complex in rat small intestine , 1993 .
[16] C. Beglinger,et al. Somatostatin 28 and coupling of human interdigestive intestinal motility and pancreatic secretion. , 1992, Gastroenterology.
[17] J. Holst,et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.
[18] G. Boeckxstaens,et al. Nitric oxide as an inhibitory non-adrenergic non-cholinergic neurotransmitter , 1990, Nature.
[19] G. Weir,et al. Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3',5'-monophosphate formation. , 1990, Endocrinology.
[20] V. Grill,et al. Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. , 1990, Metabolism: clinical and experimental.
[21] W. Fujimoto,et al. Effects of Glucagonlike Peptide l-(7–36) on Release of Insulin, Glucagon, and Somatostatin by Rat Pancreatic Islet Cell Monolayer Cultures , 1989, Diabetes.
[22] P. Hellström,et al. Neuropeptide Y Inhibits the Migrating Myoelectric Complex and Delays Small Intestinal Transit in Rats , 1989 .
[23] M. Namba,et al. Glucagonostatic and Insulinotropic Action of Glucagonlike Peptide I-(7–36)-Amide , 1989, Diabetes.
[24] S. Ohashi,et al. Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. , 1989, Endocrinology.
[25] J. Holst,et al. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. , 1988, Endocrinology.
[26] K. Shima,et al. Effect of glucagon-like peptide-1 on insulin secretion , 1988, Regulatory Peptides.
[27] S. Bloom,et al. GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.
[28] I. Goldfine,et al. Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans. , 1987, The Journal of clinical endocrinology and metabolism.
[29] A. Wilks,et al. Identical mRNA for preproglucagon in pancreas and gut. , 1987, European journal of biochemistry.
[30] G. Weir,et al. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. , 1987, The Journal of clinical investigation.
[31] J. Holst,et al. Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut , 1987, FEBS letters.
[32] J. Holst,et al. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. , 1986, Endocrinology.
[33] L. Orci,et al. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. , 1986, The Journal of biological chemistry.
[34] P. Hellström,et al. Correlation between peptide YY-induced myoelectric activity and transit of small-intestinal contents in rats. , 1985, Scandinavian journal of gastroenterology.
[35] G. Vantrappen,et al. Somatostatin induces ectopic activity fronts of the migrating motor complex via a local intestinal mechanism. , 1984, Gastroenterology.
[36] V. Grill,et al. A stimulating effect of glucose on somatostatin release is impaired in noninsulin-dependent diabetes mellitus. , 1984, The Journal of clinical endocrinology and metabolism.
[37] P. Hellström,et al. Influence of fasting and bombesin-induced myoelectric activity on the transit of small-intestinal contents in the rat. , 1984, Scandinavian journal of gastroenterology.
[38] S. Efendić,et al. Effects of cholecystokinin, gastric inhibitory polypeptide, and secretin on insulin and glucagon secretion in rats. , 1982, Endocrinology.
[39] T. Burks,et al. Accurate measurement of intestinal transit in the rat. , 1981, Journal of pharmacological methods.
[40] K. Kelly,et al. Inhibition of canine interdigestive proximal gastric motility by cholecystokinin octapeptide. , 1981, The American journal of physiology.
[41] J. Fioramonti,et al. Electrical spiking activity and propulsion in small intestine in fed and fasted rats. , 1975, Gastroenterology.
[42] J. Brown,et al. Identification and actions of gastric inhibitory polypeptide. , 1975, Recent progress in hormone research.
[43] M. Hjelm,et al. A METHODOLOGICAL STUDY OF THE ENZYMATIC DETERMINATION OF GLUCOSE IN BLOOD. , 1963, Scandinavian journal of clinical and laboratory investigation.
[44] J. Barre,et al. Contributions A L'Étude Des Variations Physiologiques De La Sécrétion Interne Du Pancreas , 1929 .
[45] Zunz Edgard,et al. Contributions a l’étude des variations physiologiques de la sécrétion interne du pancréas relations entre les sécrétions externe et interne du pancréas , 1929 .